{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:54:08Z","timestamp":1762300448443,"version":"3.41.2"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Updated vaccine strategies are needed to protect against new SARS-CoV-2 variants with increased immune escape. Here, information on the safety and immunogenicity of an inactivated Omicron-adapted vaccine is presented, as compared with CoronaVac.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A randomized, double-blind, active-controlled, phase III clinical trial was conducted to compare a modified Omicron-adapted vaccine (Omicron vaccine) with the authorized prototype vaccine (CoronaVac\u00ae) as a booster dose. Healthy adults aged \u226518 years, who have previously received 2 or 3 doses of CoronaVac (2C or 3C cohort) at least 6 months before, were enrolled to get a booster dose of Omicron vaccine or CoronaVac in a ratio of 2:1 (2C\/3C+1O\/1C). Back-up serums after two initial doses of CoronaVac (2C+0) for adults aged 26-45 years were collected from a previous study. Immunogenicity and safety data at 28 days after vaccination were collected and analyzed. One of the primary objectives was to evaluate the superiority of immunogenicity of Omicron vaccine booster against Omicron BA.1, compared with CoronaVac booster against BA.1. Another objective was to evaluate the non-inferiority of immunogenicity of Omicron vaccine booster against BA.1, compared with two initial doses of CoronaVac against ancestral strain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between June 1<jats:sup>st<\/jats:sup> and July 21<jats:sup>st<\/jats:sup>, 2022, a total of 1,500 healthy adults were enrolled. Results show that all pre-specified superiority criteria for BA.1 neutralizing antibody were met. Specifically, within the 3C cohort (3C+1O vs. 3C+1C), the geometric mean titers\u2019 (GMT) ratio and 95% confidence interval (CI) was 1.64 (1.42, 1.89), with the lower 95%CI \u22651; a GMT ratio of 1.84 (1.57, 2.16) was observed for 2C+1O versus 3C+1C. For seroconversion rate, the lower 95%CIs of differences between immuno-comparative groups (2\/3C+1O vs. 3C+1C) were all above the superiority criterion 0%. However, the non-inferiority criterion of the lower 95%CI of GMT ratio \u22652\/3 was unfulfilled for 2C\/3C+1O against BA.1 versus 2C+0 against ancestral strain. Safety profiles were similar between groups, with no safety concerns identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The Omicron-adapted vaccine was well-tolerated and could elicit superior immune responses as compared with CoronaVac against Omicron, while it appeared inferior to CoronaVac against ancestral strain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:uri>https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05381350?term=NCT05381350&amp;amp;draw=2&amp;amp;rank=1<\/jats:uri>, identifier NCT05381350.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1241153","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T07:59:08Z","timestamp":1695110348000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and immunogenicity of a modified Omicron-adapted inactivated vaccine in healthy adults: a randomized, double-blind, active-controlled Phase III clinical trial"],"prefix":"10.3389","volume":"14","author":[{"given":"Jialei","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuenan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaping","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaling","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02077-21","article-title":"Omicron: what makes the latest SARS-coV-2 variant of concern so concerning","volume":"96","author":"Jung","year":"2022","journal-title":"J Virol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taac073","article-title":"International risk of SARS-CoV-2 Omicron variant importations originating in South Africa","volume":"29","author":"Bai","year":"2022","journal-title":"J Travel Med"},{"volume-title":"Coronavirus pandemic (COVID-19)","year":"2020","author":"Mathieu","key":"B3"},{"key":"B4","doi-asserted-by":"crossref","unstructured":"The different types of COVID-19 vaccines2021","DOI":"10.4324\/9781032245706-4"},{"key":"B5","unstructured":"WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations2021"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an inactivated SARS-coV-2 vaccine in Chile","volume":"385","author":"Jara","year":"2021","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41392-022-01105-9","article-title":"Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages","volume":"7","author":"Xia","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00345-0","article-title":"Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study","volume":"22","author":"McMenamin","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072065","article-title":"Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study","volume":"379","author":"Adams","year":"2022","journal-title":"BMJ"},{"key":"B12","unstructured":"ADDENDUM to Considerations for Evaluation of COVID-19 Vaccines for Prequalification or Emergency Use Listing: Considerations for Evaluation of Modified COVID-19 Vaccines. Points to consider for manufacturers of COVID-19 vaccines2021"},{"key":"B13","unstructured":"Emergency use authorization for vaccines to prevent COVID-19: guidance for industry document2022"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02517-y","article-title":"Original SARS-CoV-2 monovalent and Omicron BA.4\/BA.5 bivalent COVID-19 mRNA vaccines: phase 2\/3 trial interim results","author":"Chalkias","year":"2023","journal-title":"Nat. Med."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213082","article-title":"Bivalent omicron BA.1-adapted BNT162b2 booster in adults older than 55 years","volume":"388","author":"Winokur","year":"2023","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent omicron-containing booster vaccine against covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2214916","article-title":"Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine","volume":"388","author":"Zou","year":"2023","journal-title":"N Engl J Med"},{"key":"B18","unstructured":"Coronavirus (COVID-19) update: FDA authorizes moderna, pfizer-bioNTech bivalent COVID-19 vaccines for use as a booster dose2022"},{"key":"B19","unstructured":"Adapted vaccine targeting BA.4 and BA.5 Omicron variants and original SARS-CoV-2 recommended for approval2022"},{"key":"B20","unstructured":"ECDC-EMA statement on booster vaccination with Omicron adapted bivalent COVID-19 vaccines2022"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30987-7","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00319-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1\/2 clinical trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B24","unstructured":"the guidelines for adverse event classification standards for clinical trials of preventive vaccines2019"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2135929","DOI":"10.1080\/21645515.2022.2135929","article-title":"Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial","volume":"18","author":"Zhu","year":"2022","journal-title":"Hum Vaccin Immunother."},{"key":"B26","unstructured":"Reflection paper on the regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-22021"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04865-0","article-title":"Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination","volume":"607","author":"Suryawanshi","year":"2022","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162192","article-title":"Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity","volume":"133","author":"Aguilar-Bretones","year":"2023","journal-title":"J Clin Invest."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq1841","article-title":"Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure","volume":"377","author":"Reynolds","year":"2022","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.31778","article-title":"Durability of immune response after COVID-19 booster vaccination and association with COVID-19 omicron infection","volume":"5","author":"Gilboa","year":"2022","journal-title":"JAMA Network Open"},{"key":"B31","doi-asserted-by":"publisher","first-page":"103904","DOI":"10.1016\/j.ebiom.2022.103904","article-title":"Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong","volume":"77","author":"Peng","year":"2022","journal-title":"eBioMedicine"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/resp.14191","article-title":"Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong","volume":"27","author":"Mok","year":"2022","journal-title":"Respirology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taac119","article-title":"Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case-control study","volume":"29","author":"Wan","year":"2022","journal-title":"J Travel Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1241153\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T07:59:13Z","timestamp":1695110353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1241153\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2023.1241153"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1241153","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2023,9,18]]},"article-number":"1241153"}}